pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
Sep 18, 26
Electra amasses $350M in biotech’s latest big IPO
biopharma dive
Sep 17, 26
Kennedy renews attacks on vaccines at Children’s Health Defense conference
stat
Sep 17, 26
STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease
stat
Sep 17, 26
Two more biotechs, Marea and North Immunology, do reverse mergers
endpoints
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Sep 17, 26
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
Sep 17, 26
STAT+: New startup to test psychedelic-like drug against Parkinson’s symptom
stat
Sep 17, 26
Webinar: Manufacturing in Turbulent Times
biospace
Sep 17, 26
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
biospace
Sep 17, 26
STAT+: A Sellas immunotherapy study, long delayed, will end in failure
stat
Sep 17, 26
STAT+: A biotech hedge fund births a new immunology company
stat
Sep 17, 26
Roche turns to Dualitas to find new bispecific approaches for immunology
endpoints
Sep 17, 26
Roche, Dualitas team up to find bispecific drugs for immune diseases
biopharma dive
Sep 17, 26
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
fiercebiotech
Sep 17, 26
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
Sep 16, 26
Sling banks $123M for an experimental thyroid eye disease pill
biopharma dive
Sep 16, 26
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
Sep 16, 26
Sling catches $123M series C for thyroid eye disease pill
biospace
Sep 16, 26
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
Sep 16, 26
5 biotechs braving the commercial waters with product launches
biospace
Sep 15, 26
Gias Foods, Inc. Recalls Bettergoods Authentic Italian Lemon Alfredo Fettuccine Because of Possible Health Risk
fda recalls
Sep 15, 26
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
fiercebiotech
Sep 15, 26
Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
biospace
Sep 15, 26
STAT+: Obesity drugmakers are testing in kids as young as 6
stat
Sep 15, 26
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
Sep 15, 26
Vera eyes full approval for Trutakna in IgAN following positive readout
endpoints
Sep 15, 26
RegCell lands $44M Series A to take Nobel-winning Tregs into clinic
endpoints
Sep 15, 26
STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trial
stat
Sep 15, 26
Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure
fiercebiotech
Sep 15, 26
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
← prev
page 15 of 34
next →